Urologix Shares Grow 53% In April, Driven By Profitability; OTC Index Flat
This article was originally published in The Gray Sheet
Executive Summary
Wall Street onlookers appear satisfied with Urologix' plan to maintain its current sales force and marketing strategy to fend-off competition in the benign prostatic hyperplasia therapy market as the firm's stock jumped 53% in April